Optiblock Coil Embolization for Neurovascular Conditions with Improved Functional Outcomes

Optiblock coils are a next‐generation detachable coil platform engineered for dense, controlled mechanical occlusion of vessels. Its integrated anchor‐basket‐fill architecture, extended lengths (up to 65 cm vs. 20 cm for many conventional coils) , and excellent fluoroscopic visibility enable high packing efficiency with fewer deployments and precise, proximal control. Compared with particle or liquid embolysate, a coil‐forward approach may limit distal spread and reduce the risk of reflux into dangerous anastomoses. Additionally, deliverability through standard microcatheters and conformability in small‐caliber or tortuous vessels support use across diverse neurovascular indications, including embolization of dural arteriovenous fistulas (dAVFs), middle meningeal artery (MMA) for chronic subdural hematoma, venous diverticula and emissary veins for pulsatile tinnitus (PT), internal maxillary artery (IMA) for temporomandibular joint‐related pathology, spinal vascular malformations, parent‐vessel sacrifice, and preoperative tumor embolization.We conducted a retrospective, single‐center cohort study of adults undergoing embolization with one or more Optiblock coils. Demographics, coil utilization, adjunct agents, radiation metrics, and hospitalization course were abstracted from the electronic health record. Pre‐operative and post‐operative notes were reviewed, and modified Rankin Scale (mRS) scores were assigned to assess functional status. Longitudinal change was tested with a Friedman test (α = 0.05).Ninety‐five patients (mean age 59; 47% male) underwent embolization using Optiblock coils for the indications above. Across the cohort, an average of 7 Optiblock coils were used per procedure with a mean total Optiblock length of 117 cm. Additional non‐Optiblock coils were used in 33% of patients. The mean Optiblock length per coil was 16.7cm. Embolysate was used with coils in 20% of patients, predominantly for tumor embolization or dAVF occlusion. Patients spent an average of 8.5 days in the hospital. Average procedure length was 124.55 minutes, and mean fluoroscopy time was 55.69 minutes. Mean skin dose per procedure was 1871.74 mGy. Functional outcomes improved over time: mRS decreased from 1.07 ± 1.51 pre‐procedure to 0.75 ± 1.21 at first follow‐up and 0.63 ± 1.05 at last follow‐up (p < 0.001). Five (5%) intraoperative complications occurred, all managed during the procedure with no long‐term deficits. Six deaths (6%) occurred, all attributable to cardiovascular comorbidities and not related to this neuroendovascular procedure or the patient's underlying neurological disease.In this single‐center, multi‐indication cohort, Optiblock coils enabled dense, controlled mechanical occlusion with low intraoperative complication rates and significant gains in functional status across diverse neuroendovascular indications. The platform's design facilitates efficient packing with fewer deployments and precise proximal control, supporting coil‐forward or hybrid strategies particularly when use of particle or liquid embolics is contraindicated. These data underscore Optiblock's versatility across a range of clinical applications. Prospective, indication‐specific studies, comparing coil‐only, liquid/particle‐only, and hybrid approaches, are warranted to define comparative effectiveness and optimize patient selection and workflow.